ANI Pharmaceuticals (ANIP)  said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of ...

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a ...

ANI Pharmaceuticals acquiring Alimera Sciences for $5.50 per share with potential for $0.50 per share CVR, offering an ...

The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...

Alimera Sciences (ALIM) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Alimera Sciences files lawsuit against ANI Pharmaceuticals over failed merger, causing stock to plummet 25% in premarket ...

Oren Livnat has given his Buy rating due to a combination of factors including the recent acquisition of Alimera Sciences by ANI Pharmaceuticals, which is expected to be immediately accretive to the ...

Alpharetta-based Alimera (NASDAQ:ALIM) Sciences Inc. (NASDAQ:ALIM) has finalized its merger with ANI Pharmaceuticals (NASDAQ:ANIP), Inc., as announced in a recent SEC filing. The pharmaceutical ...

Alimera Has Filed Lawsuit in the Delaware Court of Chancery to Compel ANI to Close Merger Transaction and Honor its Contractual Obligations Alimera Shareholders Approved Merger Agreement on ...

16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences ...

Alpharetta-based Alimera (NASDAQ:ALIM) Sciences Inc. (NASDAQ:ALIM) has finalized its merger with ANI Pharmaceuticals (NASDAQ:ANIP), Inc., as announced in a recent SEC filing. The pharmaceutical ...